Bates therapy
1 paper4 findings
- 1 lab in 1 country
- Human trial1
Outcomes
4VFQ-25
upin humans1
1 study
VFQ-25
upin humans1
Bates therapy improves VFQ-25 in humans (from 45.2 ± 10.5 to 72.8 ± 8.2 (P < 0.001)).
“VFQ-25 score from 45.2 ± 10.5 to 72.8 ± 8.2 (P < 0.001)”
Human trialelderly residents of old age homessupervised eye relaxation and movement exercises30 min twice daily30 daysn = 60
Journal of pharmacy & bioallied sciencesJan 1, 2026
Contrast sensitivity
upin humans1
1 study
Contrast sensitivity
upin humans1
Bates therapy improves contrast sensitivity in humans (from 1.20 ± 0.30 to 1.65 ± 0.25 (P < 0.001)).
“contrast sensitivity from 1.20 ± 0.30 to 1.65 ± 0.25 (P < 0.001)”
Human trialelderly residents of old age homessupervised eye relaxation and movement exercises30 min twice daily30 daysn = 60
Journal of pharmacy & bioallied sciencesJan 1, 2026
Visual field
upin humans1
1 study
Visual field
upin humans1
Bates therapy improves visual field in humans (from 3.70 ± 0.60 to 4.55 ± 0.45 (P < 0.001)).
“visual field from 3.70 ± 0.60 to 4.55 ± 0.45 (P < 0.001)”
Human trialelderly residents of old age homessupervised eye relaxation and movement exercises30 min twice daily30 daysn = 60
Journal of pharmacy & bioallied sciencesJan 1, 2026
Visual acuity
upin humans1
1 study
Visual acuity
upin humans1
Bates therapy improves visual acuity in humans (from 1.85 ± 0.55 to 3.60 ± 0.50 (P < 0.001)).
“Mean visual acuity improved from 1.85 ± 0.55 to 3.60 ± 0.50 (P < 0.001)”
Human trialelderly residents of old age homessupervised eye relaxation and movement exercises30 min twice daily30 daysn = 60
Journal of pharmacy & bioallied sciencesJan 1, 2026